NCT00295503

Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma

A Phase II Trial of Cisplatin, Pemetrexed and Bevacizumab in Untreated Malignant Mesothelioma

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 53 (actual)
• Sponsor: University of Texas Southwestern Medical Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To estimate the time to progression of cancer in patients with previously untreated mesothelioma receiving cisplatin, pemetrexed and bevacizumab

Detailed description

Secondary endpoints will include: objective response rate overall survival In addition, the objective of the analysis of the correlative science data is to determine any association between tumor expression of VEGF/KDR complex and/or the presence of sv40 (as detected by PCR amplification) and objective response.

Conditions

• Mesothelioma

Interventions

Type	Name	Description
DRUG	bevacizumab	15 mg/kg IV every 3 weeks
DRUG	cisplatin	75 mg/m2 IV every 3 weeks
DRUG	pemetrexed	500 mg/m2 every 3 weeks

Timeline

• Start date: 2006-02-01
• Primary completion: 2010-06-01
• Completion: 2010-08-01
• First posted: 2006-02-23
• Last updated: 2020-10-20
• Results posted: 2017-01-05

Locations

1 site across 1 country: United States